Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission

Inclusion Criteria: * asymptomatically infected individuals with any P. falciparum parasite density Exclusion Criteria: * age \< 15 years or \> 25 years * malaria parasite density ≥ 10,000 parasites/µL * clinical symptoms indicating severe malaria * axillary temperature ≥ 37.5°C * Body Mass Index (BMI) below 18 or above 32 kg/m2 * haemoglobin concentration below 11 g/dL * taken ivermectin in the last three months * Loa loa as assessed by questionnaire, clinical examination and parasitological assessments * for women: pregnancy or lactation * known hypersensitivity to AL or IVM * history and/or symptoms indicating chronic illness * current use of tuberculosis or anti-retroviral medication * unable to give written informed consent * unwillingness to participate in two membrane feeding assays * travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan. If a potential participant has ever visited one or more of these countries, he or she will not be eligible for enrolment. * history of cardiovascular disease. * taking drugs that are known to influence cardiac function and to prolong QTc interval, such as class IA and III: neuroleptics, antidepressant agents, certain antibiotics including some agents of the following classes - macrolides, fluoroquinolones, imidazole, and triazole antifungal agents, certain non-sedating antihistaminics (terfenadine, astemizole) and cisapride. * known disturbances of electrolyte balance, e.g. hypokalaemia or hypomagnesaemia. * taking drugs which may be metabolized by cytochrome enzyme CYP2D6 (e.g., flecainide, metoprolol, imipramine, amitriptyline, clomipramine).